Anthrax Treatment Market

Market Overview

Global Anthrax Treatment market size was valued at USD 332.06 million in 2022. It is projected to reach USD 636.65 million by 2031, growing at a CAGR of 7.5% during the forecast period (2023-2031).

Anthrax Therapeutics are used to treat infections caused by Bacillus anthracis transmitted by livestock. Anthrax spores are transmitted through various routes including cutaneous, inhalation, injection, and gastrointestinal. The spores, when activated, release toxic substances that can cause swelling, internal bleeding, and tissue death. Today, the incidence of anthrax has reduced to a great extent in developed countries as a result of improved industrial hygiene and vaccination program. However, the rate incidence is high among underdeveloped and developing countries wherein routine vaccination programs against anthrax does not exist.

Market Dynamics

Post-September 2001 bioterrorism attack in the U.S, the market witnessed drastic changes and intensified research activities in anthrax therapeutics.  Global anthrax treatment market is projected to witness considerable growth on account of growing funding to conduct research and development activities in anthrax therapeutics and various strategies by the government agencies for stockpiling. Anthim injection, Anthrasil, BioThrax, Ciprofloxacin, and Doxycycline are some of the leading FDA approved anthrax therapeutics.

Regional Analysis

Geographically, the global anthrax treatment market is segmented into four regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).

North America dominated the global market in 2018 owing to high government funding, supportive strategies, and the presence of key players in this region. The supportive strategies include National Stockpile Strategy, vaccination campaign, and Anthrax Vaccine Immunization Program, conducted by the U.S. Department of Defense, wherein over 3.2 million people received more than 13.1 million doses of vaccines between 1998 to 2015.

Asia Pacific is another leading regions in terms of market growth as anthrax is one of the common endemics in China, and in recent years, several anthrax outbreaks have been reported in China. From 2018, nearly 106 cases of anthrax were reported in the country. The Chinese government is taking efforts and initiatives to mitigate the risk of anthrax.

Anthrax is a rear disease in Europe as only a few numbers of cases reported per year. In 2014, nearly 16 cases of anthrax were reported in EU/EEA countries. To mitigate the risk of anthrax-related bioterrorism, European Commission formed a preparedness and response program for attacks by biological and chemical agents (BICHAT) in 2002. In 2012, the U.S. agreed to fund USD 6.5 million to support the U.K’s Health Protection Agency for developing anthrax vaccine .

LAMEA is presently in the nascent phase of market growth. However, the presence of a large number of populations in contact with the livestock represents favorable market opportunities.

Segmental Analysis

Global anthrax treatment market is segmented by route of transmission, drug class, and end-use.

By route of transmission, the market is segmented into cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax, and injection anthrax. In most of the reported cases, the cutaneous route is the most common, accounting for more than 80% of the cases. As per the European Centre for Disease Prevention and Control, nine cases of cutaneous anthrax were reported from Hungary in 2014. Moreover, the transmission from the gastrointestinal route is also rising with increasing consumption of raw uncooked meat.

By treatment type, the market is segmented into antibiotics, monoclonal antibodies, and others. New drug development and approvals are the key factors attributing to the overall market growth. For instance, in March 2016, the U.S. FDA approved obiltoxaximab injection, ‘Anthim,’ for treating inhalation anthrax and in November 2015, Emergent BioDefense Operations Lansing LLC received FDA approval for its Anthrax Vaccine Adsorbed, BioThrax. Issuance of emergency dispensing information, by the U.S. FDA is also boosting the market growth.

By end use, the market is segmented into hospitals and clinics, ambulatory surgery centers, government agencies, and others. Government agencies accounted for the largest revenue share, nearly 86.7% of the product sales of Emergent Biosolutions, Inc. were to the government agencies. Altimune, Inc., another leading market player, has stated that all its revenue had been derived from grants and the U.S. government contracts.